Next-Generation CAR T-cell Therapies.
Next-Generation CAR T-cell Therapies.
复制标题
DOI：
10.1158/2159-8290.cd-21-1683
复制
发表时间：
2022-07-06
期刊：
影响因子：
28.2
通讯作者：
中科院分区：
文献类型：
--
作者：
CD19和B细胞成熟抗原（BCMA）导向的CAR T细胞在B细胞和浆细胞恶性肿瘤难治性患者亚群中实现了前所未有的反应，导致美国食品药品监督管理局（FDA）批准其用于治疗白血病，淋巴瘤和骨髓瘤。这些“活性药物”可以成为合成免疫系统的一部分，在某些患者中至少持续十年。然而，尽管有这种巨大的影响，血液系统恶性肿瘤和实体癌患者的治疗需求仍显着未得到满足。从这个角度来看，我们强调了最近的创新，这些创新推动了该领域朝着未来更有效和更通用的细胞免疫疗法的方向发展。
CD19 and B-cell maturation antigen (BCMA) - directed CAR T cells have enabled unprecedented responses in a subset of refractory patients with B-cell and plasma cell malignancies, leading to their approval by the US Food and Drug administration (FDA) for the treatment of leukemia, lymphoma, and myeloma. These “living drugs” can become part of a synthetic immune system, persisting at least a decade in some patients. However, despite this tremendous impact, significant unmet treatment needs remain for patients with hematological malignancies and solid cancers. In this perspective, we highlight recent innovations that advance the field toward production of a more potent and universal cellular immunotherapy of the future.